We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

Regeneron Pharmaceuticals plans to purchase 23andMe just two months after the genetics company filed for bankruptcy.

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered ...

Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our ...

Regeneron will not acquire 23andMe's Lemonaid Health telehealth business. "We have deep experience with large-scale data management," Regeneron co-founder George Yancopoulos said in a statement.

Regeneron Pharmaceuticals ... measures the risks to and impacts on climate change through its enterprise risk management (ERM) program. Moreover, the health powerhouse has set environmental ...

Regeneron pledged to comply with 23andMe’s privacy policy, which allows customers to have their personal information deleted upon request. “We have deep experience with large-scale data management,” ...

“Regeneron is committed to advancing better ... sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a ...

Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution for improving the management of chronic obstructive ...